Table 1. Meta-analysis of the different clinical outcomes of chikungunya disease.
Presented are the number of studies and number of subpopulations reporting on the specific outcomes, the pooled estimates, confidence intervals and I2 of the estimated endpoints. CI: confidence interval. I2: I-squared statistic of heterogeneity.
| Endpoint | Studies | Subpop | Total | Pooled | 95%CI | I 2 | |
|---|---|---|---|---|---|---|---|
| Target Population | Symptoms | ||||||
| Arthralgia | 22 | 30 | 3714 | .897 | .827–.940 | 93% | |
| Arthritis | 9 | 14 | 1622 | .175 | .089–.315 | 94% | |
| Fatigue | 7 | 10 | 1291 | .560 | .389–.718 | 95% | |
| Fever | 17 | 24 | 3490 | .878 | .849–.902 | 75% | |
| Headache | 18 | 25 | 2423 | .495 | .375–.616 | 95% | |
| Joint Swelling | 7 | 9 | 632 | .500 | .410–.589 | 85% | |
| Myalgia | 17 | 19 | 2588 | .629 | .483–.754 | 97% | |
| Nausea | 8 | 10 | 968 | .347 | .156–.604 | 96% | |
| Rash | 21 | 28 | 2990 | .443 | .350–.539 | 92% | |
| Vomiting | 11 | 17 | 1446 | .171 | .113–.249 | 88% | |
| Hospitalization | |||||||
| Acute Phase | 9 | 9 | 1700 | .170 | .036–.528 | 97% | |
| General Population | Chronic rate | ||||||
| Month 3 | 17 | 17 | 2805 | .438 | .313–.572 | 97% | |
| Month 6 | 10 | 10 | 1899 | .343 | .248–.454 | 97% | |
| Month 12 | 11 | 11 | 2366 | .318 | .215–.443 | 96% | |
| Mortality rate | |||||||
| High Risk | 5 | 7 | 325206 | .1534 | .0713–.2994 | 97% | |
| Low Risk | 30 | 37 | 2518 | .0032 | .0014–.0074 | 87% | |
| Symptomatic rate | |||||||
| Overall | 8 | 8 | 1217 | .749 | .630–.840 | 91% | |